Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator

Richard L. Koller, David C. Anderson

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral hemorrhage. To decrease the risk, tPA use must be administered in an intensive care setting and directed by physicians with expertise in diagnosing and managing stroke.

Original languageEnglish (US)
Pages (from-to)221-231
Number of pages11
JournalPostgraduate medicine
Volume103
Issue number4
DOIs
StatePublished - Apr 1998

Fingerprint Dive into the research topics of 'Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator'. Together they form a unique fingerprint.

Cite this